Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

MBX Biosciences (MBX) Non-Current Assets (2023 - 2026)

MBX Biosciences has reported Non-Current Assets over the past 4 years, most recently at $4.2 million for Q1 2026.

  • Quarterly results put Non-Current Assets at $4.2 million for Q1 2026, up 152.42% from a year ago — trailing twelve months through Mar 2026 was $12.7 million (up 161.68% YoY), and the annual figure for FY2025 was $3.6 million, up 188.63%.
  • Non-Current Assets reached $4.2 million in Q1 2026 per MBX's latest filing, up from $3.6 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $4.2 million in Q1 2026 and bottomed at $715000.0 in Q4 2023.
  • Median Non-Current Assets over the past 4 years was $2.0 million (2025), compared with a mean of $2.2 million.
  • The largest annual shift saw Non-Current Assets soared 74.69% in 2024 before it soared 188.63% in 2025.
  • Over 4 years, Non-Current Assets stood at $715000.0 in 2023, then skyrocketed by 74.69% to $1.2 million in 2024, then skyrocketed by 188.63% to $3.6 million in 2025, then grew by 15.53% to $4.2 million in 2026.
  • Business Quant data shows Non-Current Assets for MBX at $4.2 million in Q1 2026, $3.6 million in Q4 2025, and $2.6 million in Q3 2025.